Abstract. The aim of the present study was to investigate the cytotoxic activity of cytokine-induced killer (CIK) cells targeted by an epidermal growth factor receptor (EGFR)/CD3 bispecific antibody (BsAb) to the gastric cancer cell line SGC7901. 
Introduction
At present, gastric cancer is an extremely common malignancy. Although the incidence of the disease has been declining for the past few decades, each year ~798,000 people are diagnosed with gastric cancer worldwide (9.9% of total cancer cases) and 628,000 people succumb to the disease (12.1% of cancer mortalities) (1) . Globally, the majority of cases of gastric cancer have been in East Asia, in countries such as China, Japan and Korea. In China, the overall prognosis for this cancer remains poor since the majority of patients are diagnosed with advanced disease due to the lack of an effective screening method or strategy. Consequently, the 1-and 5-year survival rates of patients suffering from gastric cancer are extremely low (2) . Although adjuvant treatments, including chemotherapy and radiotherapy are frequently used, their overall impact on the prognoses of these patients remains limited and their adverse reactions frequently affect the patients' quality of life. A new therapeutic strategy may be an urgent requirement for gastric cancer therapy.
Cellular immunotherapy against solid tumors has become a promising treatment following a number of preclinical and clinical trials. Of the numerous effector cells, cytokine-induced killer (CIK) cells have received considerable attention. CIK cells are expanded in vitro from peripheral blood mononuclear cells (PBMCs) by the addition of interferon-γ (IFN-γ), interleukin (IL)-2, IL-1 and a monoclonal antibody (McAb) against CD3 (3, 4) . CIK cells are highly efficient cytotoxic effector cells with the co-expression of CD3 and CD56 and NK activity (5) . CIK cells have been used as effector cells in the adoptive cell therapy against certain cancers and have shown a promising effect (6, 7) .
Bispecific antibodies (BsAbs) are antibodies which are made by chemical or biological methods and not observed in natural conditions. They are typically designed to recognize a specific epitope on effector cells and a target epitope on tumor cells simultaneously. In comparison with conventional mAbs, BsAbs are able to link immune effector cells to tumor cells directly and have a more powerful ability to activate the immune-mediated destruction of cancer cells. In 1994, Beun et al (8) reported that BsAbs directed to a target-cell surface antigen and the T-cell-receptor (TCR)/CD3-complex mediated the activation of T cells and the induction of target-cell lysis by the activated cells. Therapeutic strategies using BsAbs have been performed in a number of basal and preclinical studies (9) (10) (11) (12) (13) Hospital. DMEM containing 10% calf serum, 100 IU/ml penicillin and 100 IU/ml streptomycin was used as a conventional culture medium. The culture procedures were performed at 37˚C, 5% CO 2 and saturation humidity.
Investigation of EGFR expression in the SGC7901 cell line.
The expression of EGFR in SGC7901 cells was detected to determine whether the cell lines were suitable for use in the study. An immunocytochemical assay and RT-PCR were performed and the results showed that EGFR was expressed in the cell line.
Production of crosslinked anti-CD3 and anti-EGFR BsAb.
The anti-CD3 x anti-EGFR (EGFR/CD3) BsAb was produced using the chemical heteroconjugation technique described previously by Sen et al (14) . Anti-CD3 McAb (1 mg/ml) in 50 mM NaCl and 1 mM EDTA at pH 8.0 was added to a 5-fold molar excess of Traut's reagent (2-iminothiolane HCl; Pierce, Rockford, IL, USA) at room temperature for 1 h. Anti-EGFR (1 mg/ml) in 0.1 mol/l sodium phosphate and 0.15 mol/l NaCl (pH 7.2) were then added to a 4-fold excess of sulfosuccinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (Pierce) at room temperature for 1 h. The two antibodies were purified on PD-10 columns (Pharmacia, Uppsala, Sweden) in PBS to remove the unbound cross-linker. The cross-linked McAbs were mixed immediately in equimolar ratios and conjugated at 4˚C overnight. The product was analyzed using SDS-PAGE (2-15% gradient; OWL Scientific, Woburn, MA, USA) and detected using Coomassie blue staining.
Preparation of CIK cells. The CIK cells were prepared according to the method in the study by Tita-Nwa et al (15) . PBMCs were isolated from healthy donors via the blood bank of Beijing.
PBMCs were isolated by Ficoll density gradient centrifuging, washed with RPMI-1640 and then resuspended in RPMI-1640 containing 10% calf serum, 100 IU/ml penicillin, 100 IU/ml streptomycin and INF-γ (500 U/ml). On day 1, IL-2 (400 U/ml), IL-1α (100 U/ml) and anti-CD3 McAb (20 ng/ml) were added. The culture media were changed every 2 days and the concentration of the cells was regulated to 2x10 6 /ml. The cells were cultured for 21 days and detected using a flow cytometry assay. 
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Cytotoxicity assays.
51
Cr release assays were performed to detect the cytotoxicity of CIK cells to gastric cancer cells targeted by EGFR/CD3 BsAb as described previously by Hoyle et al (16) and Chan et al (17) . SGC7901 cells (1x10 6 ) were labeled with 300 µCi sodium chromate (Dupont-NEM, Boston, MA, USA). The labeled cells were then washed twice with PBS, suspended in RPMI-1640 and plated in 96-well plates at 1x10 4 
Investigation of EGFR and CD3 expression in tumor tissues
following treatment. The expression levels of EGFR and CD3 in the tumor tissues of the xenograft mice following treatment were detected to determine whether the effector cells were able to migrate into the tumor tissues. The tumors were dissected and embedded in paraffin. Tissue sections of 5-µm thickness were cut from paraffin-embedded tissue blocks, then H&E staining and immunohistochemical assays were performed.
Statistical analysis. In present study, the data are expressed as mean ± SD. One-way ANOVA test and the Student's t-test were performed. All data were analyzed with the SPSS 11.0 (SPSS Inc., Chicago, IL, USA) statistical software package. P<0.05 was considered to indicate a statistically significant difference.
Results
Expression of EGFR in SGC7901 cells.
The expression of EGFR in the gastric adenocarcinoma cell strain SGC7901 was detected by RT-PCR and immunocytochemical analysis. The results in the SGC7901 cells were positive. The immunohistochemical assay showed that the expression of EGFR in SGC7901 cells was mainly distributed in the cell membrane and cytoplasm and there was no clear positive signal in the cell nucleus ( Figs. 1 and 2 ).
Investigation and characterization of CIK cells. The populations of cells in expanded CIK cells were analyzed using flow cytometric analysis at day 21, to evaluate the cytotoxicity of the CIK cells. The results suggested that populations of CD3 + CD8 + T cells accounted for ~64.9% and CD3 + CD56 + T cells accounted for ~33.2% (Fig. 3) . 
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Effect of CIK cells directed by EGFR/CD3 BsAb on tumor growth.
The antineoplastic activity of CIK cells directed by the EGFR/CD3 BsAb was analyzed with tumor growth and tumor reduction assays. The results are shown in Table I and Fig. 8 . The EGFR/CD3 BsAb-redirected CIK cells showed a significant enhancement of antitumor activity in the mice. The results of the tumor growth curve assay showed that the tumors in mice treated with CIK cells directed by the EGFR/CD3 BsAb grew significantly slower than those in the other groups (P<0.05; Fig. 8 ). The administration of CIK cells directed by the EGFR/CD3 BsAb caused a mean tumor reduction of 69.8%, which was higher than those of other groups (P<0.05; Table I ). The administration of CD3 McAb alone without CIK cells had no significant antineoplastic effect compared with that in the control group treated with 0.9% NaCl. CD3 McAb did not enhance the cytotoxicity of CIK cells.
Expression of EGFR and CD3 in tumor tissues following treatment.
The immunohistochemical analysis revealed marked positive expression of EGFR in the tumor tissues of all groups and the positive signals were distributed in the cytoplasm and membrane (Fig. 9) . The immunohistochemical assay showed that the expression of CD3 in the tumor tissues of the mice treated with the EGFR/CD3 BsAb-redirected CIK cells was increased significantly and the positive signals were mainly distributed in the membrane and cytoplasm (Fig. 10) . No positive signals were observed in the tumor tissues of the mice treated with antibodies alone without CIK cells. These results indicate that the EGFR/CD3 BsAb was able to direct CIK cells to tumor tissues and enhanced their cytotoxicity to gastric cancer cells in vivo.
Discussion
Although the morbidity and mortality of gastric cancer has been reduced, gastric cancer remains a common disease in East Asia, with a poor prognosis and low survival rates. In China, the prognosis of gastric cancer is poor since mass screening and early diagnosis are not feasible. The thera-peutic effects of traditional strategies are not satisfactory as the pathogenesis and molecular control of gastric cancer are poorly understood, although the involvement of a number of affecting factors has been proposed. Among these factors, cellular immune defects are common in patients with gastric adenocarcinoma, as well as other malignancies, which may have diverse effects in regulating critical antitumor functions, including immunological recognition and regulation and cytotoxicity. Therefore, cellular immunotherapy has been proposed to be an important adjunctive therapy for gastric cancer and has yielded promising effects. As the most common type of effector cell, CIK cells express the T cell marker CD3 and NK cell marker CD56 and develop cytotoxic activity against various cancer cells, including those of gastric cancer. To enhance cytotoxity and antitumor specificity, certain artificial BsAbs have been used to direct CIK cells to tumor cells in previous studies (18) (19) (20) . (17) . These results provide more support for the role of BsAbs in enhancing the cytotoxicity of CIK cells. No studies on this therapeutic strategy for gastric cancer have been reported previously, so the present study is the first to report that a EGFR/CD3 BsAb is able to enhance the cytotoxicity of CIK cells to gastric cancer cells in vitro and in vivo.
The results of the cytotoxicity assays in vivo showed that the antitumor activity of CIK cells was enhanced significantly by the EGFR/CD3 BsAb when compared with EGFR or CD3 McAbs in a nude mouse model. The present results are in agreement with those of other studies which used different BsAbs to target T cells or CIK cells to malignant cells (27, 28) . These findings have demonstrated the promising therapeutic effect and clinical potential of this strategy in a number of malignant tumors. Certain researchers (29) have used biolu- minescent imaging to serially observe the response to therapy without the need for sacrificing the experimental animals. We were unable to perform bioluminescent imaging due to a lack of equipment, but we considered that it was possible to obtain credible data using the present test methods.
The immunohistochemical assays revealed that EGFR expression was common in tumor tissues and the positive signals were distributed in the cell membrane and cytoplasm. EGFR is the most important member of the EGFR family. The overexpression of EGFR occurs in numerous human malignancies, including lung, breast, colon and gastric carcinomas (30) (31) (32) . It is well known that EGFR is associated with malignant transformation and tumorigenesis, so this molecule has been regarded as an important target in numerous preclinical and clinical studies. The overexpression of EGFR in gastric cancer has been confirmed in a number of studies (33, 34) . Certain EGFR McAbs have been generated and used against a variety of malignancies. One such antibody, cetuximab, has yielded a promising therapeutic effect in delaying gastric cancer progression (35, 36) . Consequently, EGFR was selected as the target in gastric cancer cells in the present study.
The Given the unfavorable prognosis of patients with advanced gastric cancer, there is a marked impetus to investigate new therapeutic strategies to improve the outcome for these 
